Medication mistakes differ by dementia subtype because a drug appropriate for Alzheimer's disease may be ineffective or harmful in another dementia. The key differences involve lecanemab eligibility and monitoring, unsuitable cognitive drugs, antipsychotic sensitivity, and vascular risk. A medication mistake includes choosing a drug for the wrong diagnosis, overlooking subtype-specific risks, or failing to follow required safety monitoring. Confirming the type of dementia is therefore part of medication safety, not merely a diagnostic detail.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Lecanemab requires confirmed Alzheimer's disease
- Alzheimer's cognitive drugs can be the wrong choice in FTD
- Lewy-body dementias have a special antipsychotic hazard
- Vascular dementia does not automatically justify Alzheimer's drugs
- One safety check applies to every subtype
Lecanemab requires confirmed Alzheimer's disease
Lecanemab is not a general dementia treatment. FDA labeling limits it to Alzheimer's disease with confirmed amyloid pathology, starting during mild cognitive impairment or mild dementia—the stages studied. The required safety process is equally important. According to the FDA prescribing information for Leqembi, treatment calls for a baseline MRI and additional MRIs before the third, fifth, seventh, and fourteenth infusions.
APOE ε4 testing should inform discussions about the higher risk of amyloid-related imaging abnormalities, known as ARIA. Anticoagulants and clot-dissolving thrombolytic drugs require particular caution. ARIA can resemble an ischemic stroke, while serious and sometimes fatal brain bleeding has occurred. Before treatment, the care team should verify:.
- Confirmed amyloid pathology
- Mild cognitive impairment or mild Alzheimer's dementia
- Completion of the baseline MRI
- A plan for every required follow-up MRI
- Discussion of APOE ε4 testing and ARIA risk
Alzheimer's cognitive drugs can be the wrong choice in FTD
Frontotemporal dementia, or FTD, often includes prominent changes in behavior. Automatically carrying over an Alzheimer's prescription can expose someone to adverse effects without established benefit. NICE says not to offer cholinesterase inhibitors or memantine for FTD because evidence of benefit is absent and adverse effects remain possible.
The Association for Frontotemporal Degeneration's treatment guidance adds an important distinction: cholinesterase inhibitors may worsen impulsivity or disinhibition in people with prominent behavioral symptoms, while placebo-controlled research has not shown memantine to be effective. If behavior worsens after an Alzheimer's cognitive drug is started, the prescription and diagnosis deserve review. Families should record what changed, when it changed, and whether the change followed a new drug or dose adjustment.
Lewy-body dementias have a special antipsychotic hazard
Antipsychotics can cause harm across Alzheimer's, vascular, mixed, and Lewy-body dementias. The distinctive concern in dementia with Lewy bodies and Parkinson's disease dementia is that these drugs can worsen movement problems and provoke severe sensitivity reactions. This does not make antipsychotics routine treatment in other dementias.
The UK MHRA's antipsychotic safety guidance associates the drug class with stroke or transient ischemic attack and increased mortality. In the UK, risperidone's license covers no more than six weeks for persistent aggression in moderate-to-severe Alzheimer's disease, after non-drug measures fail and a risk of harm exists. Before an antipsychotic is prescribed, ask which symptom it targets, what non-drug measures were tried, how benefit will be judged, and when the medicine will be reviewed. Lewy-body or Parkinson's disease dementia should be stated explicitly to every prescriber.
Vascular dementia does not automatically justify Alzheimer's drugs
Vascular dementia alone is not a reason to start a cholinesterase inhibitor or memantine. NICE limits these medicines to people with vascular dementia when coexisting Alzheimer's, dementia with Lewy bodies, or Parkinson's disease dementia is suspected in its dementia assessment and management recommendations. The practical question is whether the person has a mixed or coexisting dementia that changes the expected value of treatment.
If the record simply says "dementia," ask the clinician which subtype is suspected and what evidence supports the prescription. Diagnostic uncertainty can remain. In that situation, the medication plan should make the uncertainty visible rather than treating all dementias as interchangeable.
One safety check applies to every subtype
Every medication review should examine anticholinergic burden—the combined effect of medicines that block the chemical messenger acetylcholine. Commonly prescribed medicines with anticholinergic effects are associated with cognitive impairment, so several modest contributors may matter when considered together.
Bring an up-to-date list of prescription drugs, nonprescription products, and recent dose changes to the review. Ask the prescriber or pharmacist to identify avoidable anticholinergic medicines and decide which, if any, can be reduced or replaced; do not stop prescribed medication without an agreed plan.
